Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities.
Sponsor: Forest Laboratories
Terminated
Overall study status is changed to Terminated due to low enrollment
This PHASE3 trial investigates Complicated Skin and Soft Tissue Infection and is currently terminated or withdrawn. Forest Laboratories leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Forest Laboratories
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ankara, Turkey (Türkiye) , Athens, Greece , Bucharest, Romania , Córdoba, Argentina , Diyarbakır, Turkey (Türkiye) , Dundee, South Africa , Granada, Spain , Haifa, Israel , Izmir, Turkey (Türkiye) , Lodz, Poland and 12 more locations